(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 42.58% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.28%.
Harrow's revenue in 2026 is $250,042,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $14,593,867,606, with the lowest HROW revenue forecast at $13,044,961,321, and the highest HROW revenue forecast at $17,239,823,248. On average, 8 Wall Street analysts forecast HROW's revenue for 2027 to be $19,942,075,819, with the lowest HROW revenue forecast at $17,175,748,454, and the highest HROW revenue forecast at $23,325,447,150.
In 2028, HROW is forecast to generate $27,363,640,651 in revenue, with the lowest revenue forecast at $21,982,469,105 and the highest revenue forecast at $32,077,026,920.